GGrantIndex
Sort

84,503 grants matching bioinformatics

Cancer Genomics Technology Development

$789,834
Paul S. Meltzer · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Pulmonary Hypertension in Left Heart Disease

$789,618
Margaret M Redfield · Mayo Clinic Rochester · R01 · FY2025 · HL

Vascular, Pulmonary and Renal Injury

$789,558
Michael A Gimbrone · Brigham And Women'S Hospital · T32 · FY2015 · HL

THIS PROJECT AIMS TO USE A SYSTEMS-LEVEL APPROACH TO UNDERSTAND THE MECHANISM(S) UNDERLYING DISEASES CAUSED BY TWO PATHOGENS IN POTATO: THE SOIL BORNE SPONGOSPORA SUBTERRANEA F. SP. SUBTERRANEA (SSS), A PLASMODIOPHORID (PROTIST) PARASITE, AND POTATO MOP-TOP VIRUS (PMTV), WHICH IS VECTORED BY SSS. SSS INFECTION RESULTS IN POWDERY SCAB DISEASE, WHICH FORMS LESIONS AND EVENTUALLY PUSTULES ON THE EPIDERMIS OF POTATO TUBERS. SSS IS ENDEMIC TO MOST OF THE POTATO PRODUCTION AREAS IN THE U.S. INCLUDING THE PACIFIC NORTHWESTERN (PNW) STATES OF IDAHO, OREGON AND WASHINGTON. PNW PRODUCES MORE THAN 50% OF THE NATION'S POTATOES. WHEREAS POWDERY SCAB AFFECTS THE EPIDERMIS, SECONDARY INFECTION WITH PMTV RESULTS IN INTERNAL TUBER NECROSIS. DAMAGE CAUSED BY SSS AND PMTV RENDERS POTATO TUBERS UNMARKETABLE DUE TO THEIR SCABBED APPEARANCE AND NECROTIC FLESH. DAMAGED SEED TUBERS CAN ALSO BE REJECTED TO AVOID INFESTATION OF CLEAN FIELDS, CAUSING ANOTHER ECONOMIC STRESS. DESPITE MUCH RESEARCH EFFORT, EFFECTIVE FUNGICIDES OR FUMIGATION TREATMENTS FOR POWDERY SCAB DO NOT EXIST, AND CONTROL OF SSS WOULD ALSO REDUCE PMTV. THUS, THERE IS A CLEAR NEED FOR THE DEVELOPMENT OF NOVEL PATHOGEN MANAGEMENT STRATEGIES FOR THIS PEST COMPLEX. OUR LONG-TERM GOAL IS TO UNDERSTAND THE MECHANISM OF PATHOGENESIS UNDERLYING SSS AND PMTV INFECTION TO DEVELOP CRITICALLY NEEDED DISEASE MANAGEMENT STRATEGIES. A MAJOR OBJECTIVE TOWARD THAT GOAL IS UNRAVELING OF THE MOLECULAR MECHANISMS UNDERLYING THE MUTUALISTIC AND ANTAGONISTIC INTERACTIONS AMONG THE HOST PLANT, THE VIRUS, AND THE PROTIST PATHOGEN. WE HYPOTHESIZE THAT THERE IS A UNIQUE GENE REGULATORY NETWORK THAT COORDINATES EACH OF THE TWO KEY PHASES IN THIS SYSTEM: I) WHEN PMTV RESIDES WITHIN THE RESTING SPORE OF THE SSS (MUTUALISM); AND II) WHEN PMTV INFECTS THE POTATO ROOTS ALONG WITH SSS AND CAUSES DISEASE (ANTAGONISM). USING A SYSTEMS-LEVEL ANALYSIS WILL ALLOW US TO IDENTIFY CHANGES IN THOSE NETWORKS OVER TIME, SUCH THAT WE CAN CIRCUMSCRIBE GENE SETS OF MAJOR IMPORTANCE THAT UNDERLIE DISEASE SUSCEPTIBILITY, RESISTANCE AND MUTUALISM. WE PROPOSE TWO OBJECTIVES: (1) INVESTIGATE THE ANTAGONISTIC INTERACTIONS AMONG VIRUS, VECTOR AND HOST; AND (2) ELUCIDATE THE MUTUALISTIC INTERACTION BETWEEN SSS AND PMTV.PROPOSED RESEARCH IS SIGNIFICANT BECAUSE IT WILL EXPLORE A POORLY UNDERSTOOD, YET ECONOMICALLY IMPORTANT, PLANT-PROTIST-VIRUS PATHOSYSTEM. THIS PROJECT WILL BUILD A NEW MODEL SYSTEM FOR UNDERSTANDING PLANT-PROTIST-VIRUS INTERACTIONS, AND ADVANCES OUR KNOWLEDGE TO PROVIDE A PREDICTIVE PATHOGENIC MODEL FOR PLANT PROTECTION. WE EXPECT TO DEVELOP NOVEL APPROACHES FOR DATA INTEGRATION THAT FACILITATE SYSTEMS-LEVEL ANALYSIS AS WE COMBINE TRANSCRIPTOMIC AND REGULATORY APPROACHES TO IDENTIFY KEY GENE EXPRESSION MODULES. THIS KNOWLEDGE WILL LIKELY LEAD TO NOVEL INSIGHTS REGARDING HOW THE PROTIST FACILITATES VIRUS TRANSMISSION THROUGH A MUTUALISTIC INTERACTION. LASTLY, WE EXPECT THAT KNOWLEDGE GAINED COULD LEAD TO THE DEVELOPMENT OF IMPROVED CONTROL STRATEGIES FOR THE POWDERY SCAB DISEASE.THIS PROJECT WILL HAVE POTENTIALLY SIGNIFICANT ECONOMIC, ENVIRONMENTAL, AND SOCIAL BENEFITS. MANAGEMENT OF THE POWDERY SCAB DISEASE RELIES HEAVILY ON FUNGICIDES AND SOIL FUMIGATIONS (COSTING ABOUT $70.00 PER ACRE) THAT ARE ONLY PARTIALLY EFFECTIVE, ARE EXPENSIVE, AND RISKY TO FIELD WORKERS AND THE ENVIRONMENT. THIS PROPOSED WORK WILL CONTRIBUTE TOWARD IMPROVED CONTROL STRATEGIES FOR POWDERY SCAB THROUGH DETERMINING THE MOLECULAR MECHANISMS OF MUTUALISTIC AND ANTAGONISTIC INTERACTIONS AMONG THREE ORGANISMS. SUCH KNOWLEDGE WILL HELP IDENTIFY POTENTIAL MOLECULAR TARGETS TO ENGINEER DISEASE RESISTANCE INTO POTATO AND ALSO OTHER CROPS THAT SUFFER FROM SIMILAR PATHOSYSTEMS. THESE OUTCOMES WOULD BE USEFUL IN DEVELOPING ECO-FRIENDLY AND DURABLE CONTROL OPTIONS FOR DISEASES THAT CURRENTLY RELY ENTIRELY ON CHEMICAL CONTROL MEASURES. IN ADDITION, THE PROJECT WILL INTEGRATE RESEARCH AND EDUCATION THROUGH STUDENT PARTICIPATION IN A VARIETY OF WAYS. ONE PHD STUDENT AND TWO POST-DOCTORAL FELLOWS WILL BE TRAINED IN PLANT GENOMICS, MOLECULAR BIOLOGY, BIOINFORMATICS, AND VIROLOGY. SEVERAL UNDERGRADUATES WILL ALSO PARTICIPATE IN THE PROJECT. A STRONG EMPHASIS WILL BE PLACED ON RECRUITMENT AND TRAINING OF UNDERREPRESENTED GROUPS. STUDENTS' RESEARCH PROJECTS WILL ENCOMPASS THE DEVELOPMENT OF GENETIC CONSTRUCTS, PHENOTYPE ANALYSIS, AS WELL AS BIOINFORMATICS. THIS EXPOSURE WILL OFFER STUDENTS AN EMPOWERING AND EDUCATIONAL GLIMPSE INTO SCIENTIFIC RESEARCH AND PREPARE THEM FOR FUTURE CAREERS IN AGRICULTURAL SCIENCE. THUS, THE PROPOSED PROJECT INTEGRATES RESEARCH AND EDUCATION TO ACHIEVE BENEFICIAL RESULTS FOR EDUCATION, AGRICULTURE, AND THE ENVIRONMENT.

$789,500
Washington State University · · FY2020 · National Institute of Food and Agriculture

The genetic basis of Dandy-Walker and other mid-hindbrain malformations

$789,499
William B Dobyns · Seattle Children'S Hospital · R01 · FY2017 · NS

MicroRNA Predictors of HIV Risk in Reproductive Age Women

$789,436
Raina N Fichorova · Brigham And Women'S Hospital · R01 · FY2023 · HD

Core B - Clinical Core

$789,415
David A Wolk · University Of Pennsylvania · P30 · FY2017 · AG

Transcriptome resources for comparative primate models of lentivirus infection

$789,409
Guido Silvestri · Emory University · R24 · FY2015 · OD

Regulation of immunity by the cGAS-STING pathway

$789,339
Jonathan C Kagan · Boston Children'S Hospital · R01 · FY2025 · AI

Regulation of immunity by the cGAS-STING pathway

$789,339
Jonathan C Kagan · Boston Children'S Hospital · R01 · FY2024 · AI

Regulation of immunity by the cGAS-STING pathway

$789,339
Jonathan C Kagan · Boston Children'S Hospital · R01 · FY2023 · AI

Genes, Home Allergens and Asthma in Puerto Rican Children

$789,272
Juan Carlos Celedon · Brigham And Women'S Hospital · R01 · FY2009 · HL

BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES: SARS-CoV-2 ACTIVITIES

$789,214
Rick Stevens · University Of Chicago · N01 · FY2023 · AI

Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk

$789,208
Pia S Pannaraj · University Of California, San Diego · R01 · FY2024 · AI

J: NRSA Training Core

$789,195
Janice Lynn Gabrilove · Icahn School Of Medicine At Mount Sinai · TL1 · FY2023 · TR

A spatially resolved joint cortical metabolome and proteome in aging and menopause for the rhesus macaque

$789,150
Anita A Disney · Duke University · R01 · FY2023 · AG

Integrated Training in Cancer Model Systems

$789,141
Channing J Der · Univ Of North Carolina Chapel Hill · T32 · FY2017 · CA

Identifying Influenza Virus Infection Severity and Outcome Signatures Through Artificial Intelligence-driven Analyses

$788,942
Christopher L. Dupont · J. Craig Venter Institute, Inc. · R01 · FY2022 · AI

Plasma Proteomic and Metabolomic Predictors of Vascular Disease in Treated HIV

$788,897
Peter W Hunt · University Of California, San Francisco · R56 · FY2021 · HL

Michigan Institute for Clinical and Health Research (MICHR) (KL2)

$788,852
Thomas P. Shanley · University Of Michigan At Ann Arbor · KL2 · FY2011 · RR

MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes

$788,776
Jill Allison Hollenbach · University Of California, San Francisco · R01 · FY2024 · AI

A New Machine Learning Framework for Single-Cell Multi-Omics Bioinformatics

$788,711
Heng Huang · University Of Pittsburgh · · FY2022 · BIO

Expanding the Xenopus ORFeome to genome-scale by de novo cloning of protein-coding gene models

$788,707
P. Todd Stukenberg · University Of Virginia · R24 · FY2017 · OD

INIA: Stress, Anxiety of Alcohol Abuse

$788,558
Kathleen A Grant · Oregon Health & Science University · U01 · FY2006 · AA

Systematic Development of Novel, Druggable Cancer Targets

$788,540
Michael E. Berens · Translational Genomics Research Inst · U01 · FY2014 · CA